Robert Marcus
Stock Analyst at JP Morgan
(1.44)
# 3,164
Out of 4,820 analysts
21
Total ratings
47.06%
Success rate
-1.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEN Penumbra | Maintains: Overweight | $230 → $285 | $300.25 | -5.08% | 3 | Feb 19, 2025 | |
| IART Integra LifeSciences Holdings | Upgrades: Neutral | $75 | $16.79 | +346.69% | 2 | Dec 17, 2021 | |
| BDX Becton, Dickinson and Company | Downgrades: Neutral | $265 | $205.21 | +29.14% | 10 | Aug 6, 2021 | |
| GKOS Glaukos | Downgrades: Underweight | $50 | $96.68 | -48.28% | 2 | Oct 8, 2020 | |
| TMDX TransMedics Group | Downgrades: Neutral | $15 | $93.50 | -83.96% | 2 | Oct 8, 2020 | |
| ATRC AtriCure | Maintains: Overweight | $48 → $57 | $33.44 | +70.45% | 2 | Jul 29, 2020 |
Penumbra
Feb 19, 2025
Maintains: Overweight
Price Target: $230 → $285
Current: $300.25
Upside: -5.08%
Integra LifeSciences Holdings
Dec 17, 2021
Upgrades: Neutral
Price Target: $75
Current: $16.79
Upside: +346.69%
Becton, Dickinson and Company
Aug 6, 2021
Downgrades: Neutral
Price Target: $265
Current: $205.21
Upside: +29.14%
Glaukos
Oct 8, 2020
Downgrades: Underweight
Price Target: $50
Current: $96.68
Upside: -48.28%
TransMedics Group
Oct 8, 2020
Downgrades: Neutral
Price Target: $15
Current: $93.50
Upside: -83.96%
AtriCure
Jul 29, 2020
Maintains: Overweight
Price Target: $48 → $57
Current: $33.44
Upside: +70.45%